title: GATM polymorphism associated with the risk for statin-induced myopathy does not replicate in case-control analysis of 715 dyslipidemic individuals.
abstract: Statin-induced myopathy (SIM) is the most common reason for discontinuation of statin therapy. A polymorphism affecting the gene encoding glycine amidinotransferase (GATM rs9806699 G > A) was previously associated with reduced risk for SIM. Our objective was to replicate the GATM association in a large, multicenter SIM case-control study. Mild and severe SIM cases and age- and gender-matched controls were enrolled. Participants were genotyped, and associations were tested (n = 715) using chi-square and logistic regression with consideration for SIM severity and exclusion of subjects with potentially confounding comedications. The minor allele (A) frequencies of GATM rs9806699 in the controls (n = 106), mild SIM (n = 324), and severe SIM (n = 285) cases were 0.26, 0.28, and 0.29, respectively (p = 0.447). The unadjusted odds ratio for the A allele for any SIM (mild or severe) was 1.14 (0.82-1.61; p = 0.437), which remained nonsignificant in all models. Our results do not replicate the association between GATM rs9806699 and SIM.
authors: Center for Pharmacogenomics, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA. Electronic address: luzum.2@osu.edu.
authors: Jasmine A
authors: JA
authors: Luzum
authors: Center for Pharmacogenomics, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
authors: Joseph P
authors: JP
authors: Kitzmiller
authors: Department of Pediatrics, University at Buffalo, Buffalo, NY 14214, USA.
authors: Paul J
authors: PJ
authors: Isackson
authors: Department of Biostatistics, University at Buffalo, Buffalo, NY 14214, USA.
authors: Changxing
authors: C
authors: Ma
authors: Children's Hospital Oakland Research Institute, Oakland, CA 94609, USA.
authors: Marisa W
authors: MW
authors: Medina
authors: Center for Pharmacogenomics, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA; Department of Pharmaceutics and Pharmaceutical Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH 43210, USA.
authors: Anees M
authors: AM
authors: Dauki
authors: Center for Pharmacogenomics, The Ohio State University Wexner Medical Center, Columbus, OH 43210, USA.
authors: Eduard B
authors: EB
authors: Mikulik
authors: Department of Epidemiology and Environmental Health, University at Buffalo, Buffalo, NY 14214, USA.
authors: Heather M
authors: HM
authors: Ochs-Balcom
authors: Departments of Pediatrics, Neurology, and Pathology and Anatomical Sciences, University at Buffalo, Buffalo, NY 14214, USA.
authors: Georgirene D
authors: GD
authors: Vladutiu
mesh_terms: D000579:Amidinotransferases / Q000235:genetics*; D005787:Gene Frequency; D056726:Genetic Association Studies; D005838:Genotype; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects*; D016015:Logistic Models; D009135:Muscular Diseases / Q000139:chemically induced* / Q000235:genetics*; D016017:Odds Ratio; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000579:Amidinotransferases; C020681:glycine amidinotransferase